Sign In
Buy NMRA
$1.74
-0.0100 (-0.571%)
At Close: Jun 03, 2026
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference
04:05pm, Tuesday, 12'th May 2026
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
07:00am, Thursday, 07'th May 2026
KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer's disease agitation and
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
07:00am, Monday, 06'th Apr 2026
WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that tar
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
02:04pm, Wednesday, 01'st Apr 2026
LOS ANGELES, April 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeu
Traders Buy Large Volume of Call Options on Neumora Therapeutics (NASDAQ:NMRA)
02:31am, Tuesday, 31'st Mar 2026
Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) was the target of some unusual options trading activity on Monday. Stock traders acquired 2,812 call options on the company. This is an incr
Neumora Therapeutics: Downgrading After Navacaprant Development Setback
04:13pm, Monday, 30'th Mar 2026
Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the MDD primary endpoint. KOASTAL-2 and KOASTAL-3 studies for navacaprant in MDD have increased enrollme
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
11:22am, Monday, 30'th Mar 2026
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
06:53am, Monday, 30'th Mar 2026
New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
07:27pm, Thursday, 19'th Mar 2026
LOS ANGELES--(BUSINESS WIRE)---- $NMRA--NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
07:00am, Monday, 16'th Mar 2026
WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that targ
Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment
02:32pm, Tuesday, 17'th Feb 2026
NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation.
Neumora Therapeutics Highlights NMRA-511 AD Agitation Signal, Maps Higher-Dose Plan for 2026
01:02am, Monday, 16'th Feb 2026
Neumora Therapeutics (NASDAQ: NMRA) executives highlighted new clinical-scale analyses for NMRA-511 in Alzheimer's disease (AD) agitation and reviewed pipeline milestones during a presentation at the
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Hold” by Analysts
04:14am, Friday, 06'th Feb 2026
Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) has earned an average recommendation of "Hold" from the eleven research firms that are presently covering the firm, MarketBeat Ratings repor
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
07:00am, Wednesday, 04'th Feb 2026
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that targe
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of “Hold” from Brokerages
02:10am, Monday, 12'th Jan 2026
Shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA - Get Free Report) have been given an average rating of "Hold" by the ten analysts that are presently covering the stock, MarketBeat.com reports. Thr
